Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 14/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907170 | 0.88 | GRM5 (0.40) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL9382117 | 0.83 | GRM5 (0.56) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL16219043 | 0.82 | DPP4 (0.49) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL19722725 | 0.82 | DPP4 (0.46) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL13494214 | 0.82 | DPP4 (0.49) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL13063694 | 0.82 | NPC1 (0.44) | GRM5NPC1RAB9AGCK | |
| SCHEMBL12340949 | 0.82 | GRM5 (0.39) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL15889120 | 0.79 | DPP4 (0.44) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL15492431 | 0.79 | NPC1 (0.63) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL16286087 | 0.79 | DPP4 (0.52) | DPP4DPP8DPP9DPP7GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| EP-1879886-B1 | Inhibitors of mitotic kinesins and their therapeutical use | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | DPP4 2904/4885DPP8 2606/4885DPP9 2648/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | DPP4 3443/4885DPP8 2840/4885DPP9 3014/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | DPP4 3443/4885DPP8 2840/4885DPP9 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.